EDINBURGH, Scotland, Sept. 5,
2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC
BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage
biotechnology company developing platform allogeneic gamma-delta T
cell therapies for cancer and other indications today
announced it will participate at the H.C. Wainwright 26th
Annual Global Investment Conference from September 9–11, 2024 in
New York City.
The in-person venue for the event is the Lotte New York Palace
Hotel in New York City located at
455 Madison Avenue. Virtual participation will be staged
simultaneously with over 550 company presentations scheduled as
live feed or available on-demand.
Bryan Kobel, CEO of TC BioPharm,
will provide an overview of the Company's business during the
presentation. More than 550 corporate presentations & panels
are available during the event. For more information or if you are
interested in scheduling an individual meeting with management,
please contact the company directly at ir@tcbiopharm.com.
About H.C. Wainwright &
Co.
H.C. Wainwright is a full‐service investment bank dedicated to
providing corporate finance, strategic advisory and related
services to public and private companies across multiple sectors
and regions. H.C. Wainwright & Co. also provides research and
sales and trading services to institutional investors. According
to Sagient Research Systems, H.C. Wainwright's team is ranked
as the #1 Placement Agent in terms of aggregate CMPO
(confidentially marketed public offering), RD (registered direct
offering) and PIPE (private investment in public equity) executed
cumulatively since 1998. For more information visit H.C.
Wainwright & Co. on the web at www.hcwco.com
About TC BioPharm (Holdings) PLC
TC BioPharm is a clinical-stage biopharmaceutical company
focused on the discovery, development and commercialization of
gamma-delta T cell therapies for the treatment of cancer with human
efficacy data in acute myeloid leukemia. Gamma-delta T cells are
naturally occurring immune cells that embody properties of both the
innate and adaptive immune systems and can intrinsically
differentiate between healthy and diseased tissue. TC BioPharm is
the leader in developing gamma-delta T cell therapies, and the
first company to conduct phase II/pivotal clinical studies in
oncology. The Company is conducting two investigator-initiated
clinical trials for its unmodified gamma-delta T cell product line
- Phase 2b/3 pivotal trial in
treatment of acute myeloid leukemia using the Company's proprietary
allogeneic CryoTC technology to provide frozen product to clinics
worldwide.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/tcbp-announces-participation-at-the-hc-wainwright-26th-annual-global-investment-conference-302239053.html
SOURCE TC BioPharm
